Vision Sessions are informational sessions presented by industry experts. They are designed to complement your educational experience.
No CME/CE credits are offered at these sessions.
Transcranial magnetic stimulation (TMS) has been FDA-cleared in the United States for the treatment of major depressive disorder since 2009. By depolarizing neurons in targeted brain structures and increasing action potential, TMS is able to increase neuroplasticity and effectively treat refractory mental health disorders. In 2020, Deep TMS™ was cleared in the treatment of smoking addiction, the first FDA clearance in addiction medicine for any TMS system. This session will explore the completed and ongoing TMS research in the field of alcohol use disorder (AUD). By noninvasively stimulating relevant structures and circuitry in the brain, researchers have demonstrated in multiple pilot studies that TMS may be an effective tool in a multimodal approach to addressing AUD. Early results have been compelling and promising.